Janux Therapeutics, Inc. (JANX) Market Cap & Valuation Ratios
Janux Therapeutics, Inc. (JANX) has a market cap of $1.0B and a price-to-sales ratio of 42.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
JANXJanux Therapeutics, Inc.Follow JANX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| JANX | 1.0 | — | 2.0 | — | -4.1% | — | — | -16% |
| BCAX | 1.1 | — | — | — | -12.0% | — | — | -54% |
| REPL | 1.1 | — | — | — | — | — | — | -205% |
| VOR | 1.1 | — | — | — | -13.0% | — | — | — |
| AVBP | 1.0 | — | — | — | -14.3% | — | — | -101% |
| MNKD | 1.0 | — | 3.1 | 41.0 | -1.8% | +30% | 2% | 4% |
| JBIO | 0.9 | — | — | — | -13.3% | — | — | -50% |
| GLUE | 0.9 | — | 29.1 | — | -3.5% | -84% | — | -61% |
| CGEM | 0.9 | — | — | — | — | — | — | -67% |
| VSTM | 0.9 | — | 9.7 | — | — | +3996% | -183% | — |
| RIGL | 0.9 | — | 3.0 | 9.4 | 8.8% | +3% | 31% | 17% |
| Median of these 10 | — | 6.4 | 25.2 | -12.0% | +17% | 2% | -58% |
; EV/Sales 2.0 vs. 6.4.
Growth vs. price
each dot a company · hover or tap for valuesJanux Therapeutics, Inc. — questions
- What is Janux Therapeutics, Inc.'s market cap?
- $1.0B.
- What is Janux Therapeutics, Inc.'s price-to-sales ratio?
- 42.4.
Every figure on this page comes from Janux Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.